View / All
USP15 Technologies
Background Neuroinflammation is a key component of neurological diseases such as multiple sclerosis, Azheimer’s and Parkinson. The ubiquitin–proteasome system is a well-understood signaling pathway. Deubiquitinating enzymes or “DUBs” influence the system by removing the ubiquitin “tags” from substrates. Since their discovery, genetic and functional studies have nominated DUBs as a promising class for drug discovery
A novel proprietary lead with dual mechanisms to target diabetic retinopathy
Background Diabetic retinopathy, also known as diabetic eye disease (DED), is a medical condition in which damage occurs to the retina due to diabetes mellitus. It is a leading cause of blindness in developed countries. Diabetic retinopathy affects up to 80 percent of those who have had both type 1 and type 2 diabetes for 20 years or more. Non-Proliferative Diabetic Retinopathy (NPDR) represents over 50%
IMMUNOTHERAPY AND TARGETED IMMUNO-ONCOLOGY PLATFORMS
Background In nature AFP is an immune regulatory protein involved in protecting the fetus from attack by the mother’s immune system and is a carrier protein known for diverting and transporting nutrients from the mother to the embryo via AFP receptors which are found on all fetal cells. AFP receptors are also found on most
A New Gene Editing Platform Technology
Background Gene editing technology is one of the frontiers of biotechnology. However, the leading technologies cannot control editing outcomes. Current gene editors leave DNA ends that are compatible when they cut DNA allowing random length insertions / deletions and only resulting in infrequent levels of DNA repair. Tech Overview Dualase is a new gene editing
Allogeneic Cell Therapy Platform Technologies
Tech Overview The Allogeneic cell therapy platform integrates patented and licensed technologies. Induced Allogeneic cell tolerance (iACT) is achieved by cloaking genes and mitigating initiation of adaptive immunity by antigen presenting cells, blocking cytotoxic activity and modulating inflammatory and phagocytotic monocytes and macrophages. Targeted gene editing is used to edit cell division essential locus (CDEL).
Platelet Alpha Granule Storage: precision drug platform that unlocks new combination therapies and serves cancers with unmet needs
Tech Overview Platelets preferentially adhere to disease tissues because there are physical, morphological, and functional differences between normal and tumor vasculature. Tumor associated vessels consist of sprouting, leaky structures to which platelets attach and trap their cargo in situ. The platform has flexible proprietary Platelet Anchoring Ligands (PALs) that enable sequestration of compounds into different
A better delivery technology for more efficacious medicinal formulations
There are dozens of active ingredients with therapeutic benefits that have low bio-availability are poorly absorbed by our bodies. For brands & manufacturers, it’s complex and costly to implement a technology that can improve efficacy of products, get quick regulatory approval and scale at low cost Tech Overview Proprietary delivery technology greatly improves absorption and
Safe, affordable, and scalable off-the shelf natural killer (NK) cell therapeutics
CAR-T cells are an important and effective tool in the treatment of selected patients with different cancers, but they have limitations, including adverse effects from cytokine release syndrome and neurotoxicity, limited success with solid tumors, high manufacturing cost, and the challenge of generating off-the shelf products. The process of collecting, genetically modifying, and expanding patient-derived
Novel Therapeutics for compulsive disorders
Eating disorders are often complex, hard-to-treat psychiatric conditions that lead to compulsions and dysregulation of habit formation, behaviour and mental state. About 9% of the population worldwide suffer from eating disorders with anorexia nervosa (AN) having the highest mortality rate. Currently, there is no specific treatment for anorexia nervosa. Current treatment relies on traditional anti-depressant
Drug delivery platform enhancing breakdown of endosomal membranes for drug efficacy
Background Antibody Drug Conjugates (ADCs) are the future of targeted cancer therapies. However, due to limitations to their mode of action, ADCs are not completely degraded with limited drug release restricting efficacy. ADC and drug metabolites remain entrapped with ADCs being recycled back outside the cells by multiple mechanisms. Tech Overview The proprietary drug
Drug discovery platform for genetic related diseases
Genetic related diseases are often related to abnormal protein expression. A single mutated allele can lead to insufficient protein production. However, current therapeutics only treat symptoms of these diseases. Geneboost’s drug discovery platform enables real-time and non-invasive detection of protein synthesis specifically from healthy alleles for any genetic disease by simultaneously evaluating drug efficacy, specificity
Novel biomarker for Alzheimer’s Disease
Alzheimer’s disease (AD) is a neurodegenerative disease which cause is poorly understood. There are many environmental and genetic risk factors associated with its development. Dr. Gerhard Multhaup’s group discovered that the amyloid precursor protein cleaving enzyme BACE1 also possesses “amyloidolytic” activity in vivo, whereby larger amyloid peptides (e.g. neurotoxic Aβ42) are commonly degraded into
New compounds to treat triple negative breast cancers
Background Triple negative breast cancers (TNBCs) have the poorest prognosis (5-year survival rate) amongst breast cancers and represents ~15-20% of cases. The projected global market (2026) is $24.7 billion. The biggest challenge is that TNBCs lack therapeutic targetable markers (e.g., HER2, PR). Current treatments include Taxol (e.g., Abraxane) in combination with PARP inhibitors, cisplatin or
A sensing and biofeedback wearable providing gait feedback for every step
Background: Many people do no walk well enough to derive health benefits from walking and even placing themselves at risk of falls or injury. Therapists instruct people to place the heel first when walking to encourage correct gait. This simple strategy changes posture from stooped to upright and lengthens the stride. But once verbal cueing
Time Resolved Dynamic Angiographic Computed Tomography (TRD-ACT)
The clinical gold standard for assessing the functional significance of a coronary artery stenosis is the invasive fractional flow reserve (FFR) technique, in which a specialized catheter is advanced to the culprit artery with aids of fluoroscopy to measure the flow pressure gradient across a plaque during maximal hyperemia.
A dynamic knee scan used to examine the loaded knee during gait as recommended by guidelines
Background Knee disorders account for a large portion of the orthopedic visits to primary care practitioners, musculoskeletal physicians, and physical therapists. While some of these disorders are preceded by a single traumatic event, more than often they are attributed to biomechanical dysfunctions. In fact, the develop-ment of high prevalence knee conditions such as anterior knee
Next Generation non-invasive focused ultrasound platform
Tech Overview The focused ultrasound platform uses a transducer to focus ultrasound on a target deep in the body. The energy at focus point leads to bioeffects at the precise location without impacting surrounding tissues. System design and ultrasound parameters can be attenuated to selectively change between 27 known bioeffects to achieve desired effects such